No Results Found
Try adjusting your search to find what you’re looking for.
10/05/2023
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-In-Class Liquid Biopsy Platform
Precede Biosciences emerges from stealth today with a breakthrough, comprehensive, blood-based approach to revealing disease-defining transcriptional biology – a first for the diagnostic field.
Read More
10/03/2023
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
Iambic’s unique AI-Driven drug-discovery platform identifies potential first-in-class and best-in-class development candidates years faster than industry norms. Funding will support continued AI platform innovations and advancement of multiple candidates into clinical development, Including IAM-H1, a selective brain-penetrant HER2 Inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor.
Read More
9/21/2023
Illumina Ventures Announces New Partner, Mara Aspinall, Has Joined Its Investment Team
Illumina Ventures today announced that Mara Aspinall, MBA, has joined the Company’s investment team as a Partner.
Read More
9/18/2023
Broken String Biosciences Closes $15M Series A Funding Round
Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners...
Read More